Batch BeaconUK recalls and safety alerts

Medicines defect noticeMHRA

Brilique 90mg Tablets defect notice over a strength or dose problem

Wrong strength or doseLow riskClass 4

G Pharma Ltd have informed the MHRA that there is an error in the spelling of the active ingredient included on the imported carton. The spelling should be ‘Ticagrelor’ but has been printed as ‘Tricagelor’ under the brand name and in the content statement.

Check your product

Only products that match these details are covered. Have your pack in front of you.

7 identifiers listed for this notice.

  • Brilique 90mg Tablets 56 Tablet

    Batch codePrinted on the pack, often next to the date mark. It may start with L or LOT.
    • 200507 (OMB VHVK)
    • 200942 (OMB VHXF)
    • 201136 (OMB VHXF)
    ExpiryOn the carton, blister or label.
    • 31/11/2026
    • 31/01/2027
    First distributedOn the product, its label or its packaging.
    • 07/10/2024
    • 21/10/2024

What to do now

Brilique 90mg Tablets has been recalled because test results for the affected batches were outside the approved limits for strength or how the medicine dissolves.

  1. Keep taking your medicine unless a healthcare professional tells you otherwise.
  2. Check the batch number and expiry date on your pack against the list on this page.
  3. If it matches, your pharmacist can swap it or arrange an alternative.
  4. Report suspected side effects to the MHRA Yellow Card scheme.

Why it matters. A medicine that is weaker than stated may not control the condition it treats; one that is stronger may cause side effects.

Symptoms and when to get help

Look out for

  • a side effect you have not had before
  • your condition not being controlled as well as usual

Get help urgently

  • signs of a severe allergic reaction, such as swelling of the face or throat or difficulty breathing — call 999
  • if you feel unwell and are worried, speak to a pharmacist, your GP or NHS 111

This is general information based on NHS public guidance, not medical advice. In an emergency call 999. For urgent advice use NHS 111 (NHS 24 on 111 in Scotland) or, in Northern Ireland, your GP or out-of-hours service.

Replacements and prescriptions

The MHRA notice tells pharmacies and healthcare professionals what to do. Patients should keep taking their medicine and ask a pharmacist before stopping.

An affected pack bought over the counter can be returned to where you bought it.

From the official notice

Published by the Medicines and Healthcare products Regulatory Agency (EL(25)A/18). Quoted as issued.

Summary

G Pharma Ltd have informed the MHRA that there is an error in the spelling of the active ingredient included on the imported carton. The spelling should be ‘Ticagrelor’ but has been printed as ‘Tricagelor’ under the brand name and in the content statement.

The risk

DMRC reference number DMRC-34718431 Marketing Authorisation Holder

Advice for healthcare professionals

Healthcare professionals are to be aware of the incorrect spelling of the active ingredient on the carton when prescribing and or dispensing the product.

When products from batches included in the table above are supplied or dispensed, please ensure that patients are aware of the spelling mistake on the carton.

The correct spelling of the active ingredient is included in the patient information leaflet and printed on the blister foil within the packs.

Patients should continue to take medicines from the impacted batches as prescribed by your healthcare professional. This error does not affect the quality or efficacy of the product.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Advice for patients

Patients should continue to take medicines from the impacted batches as prescribed by your healthcare professional. This error does not affect the quality or efficacy of the product.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Open the MHRA notice

Questions

Why has Brilique 90mg Tablets been recalled?

Brilique 90mg Tablets has been recalled because test results for the affected batches were outside the approved limits for strength or how the medicine dissolves. A medicine that is weaker than stated may not control the condition it treats; one that is stronger may cause side effects.

How do I know if my medicine is affected?

Compare the batch code, expiry and date code on your pack with the details listed under “Check your product” on this page. Only items that match are covered by the notice.

What should I do now?

Keep taking your medicine unless a healthcare professional tells you otherwise. Check the batch number and expiry date on your pack against the list on this page.

Do I need a new prescription?

The MHRA notice tells pharmacies and healthcare professionals what to do. Patients should keep taking their medicine and ask a pharmacist before stopping. An affected pack bought over the counter can be returned to where you bought it.

Related notices